Trump's pharma investments jump to $56.2 million after 2025 drug law
Congressional Democrats report that President Trump’s pharmaceutical holdings rose from $1.7 million in 2024 to as much as $56.2 million by the end of 2025, largely in firms benefiting from a Republican-backed Medicare exemption.
According to a report released by the Joint Economic Committee’s minority arm, President Trump’s pharmaceutical stock holdings surged from a reported $1.7 million in 2024 to a peak of $56.2 million at the close of 2025. The growth is driven by up to $39.1 million in shares of companies that gained exemptions from Medicare’s drug-price negotiation program through a provision in the Republican-led 2025 tax and spending law.
Committee analysis shows Trump’s portfolio bought about $2.55 million in such stocks on three occasions before the bill’s July 2025 signing, including $950,000 on the day the Senate passed the measure and $1 million of AbbVie stock in August 2025 after the law took effect. The White House maintains the investments are handled by third-party managers with no input from the president or his family. Critics argue the exemptions could raise Medicare patients’ out-of-pocket costs for drugs like Keytruda and Opdivo by roughly $5,000 annually. Polling indicates many Americans view the gains as a conflict of interest, while supporters of the exemption say it encourages development of treatments for rare diseases.
Why it matters
The story highlights potential conflicts of interest as policy changes appear to boost the president’s personal wealth.
How the sides frame it
MODERATE AGREEMENTLeft-leaning coverage frames Trump’s pharma investments as a profiteering giveaway that harms seniors, while centrist coverage presents the increase as a factual outcome of the 2025 law and includes the White House’s explanation that third-party managers handle the investments.
LEFT
Trump’s stock surge is portrayed as a profiteering giveaway to big pharma that raises drug costs for seniors.
CENTER
The investment increase is reported factually, linked to the 2025 law’s exemptions, with the administration’s note that third-party managers control the holdings.
The left emphasises
- Trump profited from a giveaway to big pharma
- jacking up drug costs at the expense of seniors
- contradicts his promises to cut drug prices
In this story
